Key statistics
As of last trade, Chemomab Therapeutics Ltd (2QV0:BER) traded at 1.21, 201.00% above the 52 week low of 0.402 set on Dec 12, 2023.
52-week range
Open | 1.23 |
---|---|
High | 1.27 |
Low | 1.21 |
Bid | 1.15 |
Offer | 1.28 |
Previous close | 1.25 |
Average volume | 632.56 |
---|---|
Shares outstanding | 18.51m |
Free float | 4.18m |
P/E (TTM) | -- |
Market cap | 25.08m USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 15:58 BST.
More ▼
Announcements
- Chemomab Therapeutics to Present at October 2024 Investor Conferences
- Chemomab Therapeutics to Present at September 2024 Investor Conferences
- Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Therapeutics Announces Closing of $10 Million Private Placement
- Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Chemomab Therapeutics Announces $10 Million Private Placement
- Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
- Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
- Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
More ▼